Publication | Closed Access

Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21

VaccinationVaccine DevelopmentVaccine TargetMalariaImmunologyVaccine Spf66New FormulationsPlasmodium Falciparum MalariaVaccine DesignPolyvalent VaccineMedicine